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LESSONS LEARNED
x Cardiotoxicity can be a serious complication of anticancer therapies. To enable earlier identification of drug-related cardiac
effects, the International ConferenceonHarmonization (ICH) adopted the ICHE14Guidelines forevaluating thepotential forQT/
corrected QT (QTc) interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs.
x The results of the evaluation of ramucirumab on the QT/QTc interval show a lack of effect on QTc prolongation in patients with
advanced cancer.
ABSTRACT
Background. Ramucirumab is a human immunoglobulin G1
monoclonal antibody that specifically blocks vascular endo-
thelial growth factor receptor-2 and is approved for the
treatment of advanced gastric, non-small cell lung, and
colorectal cancers. This phase II study was conducted to
determine if treatment with ramucirumab causes prolonga-
tion of the corrected QT interval using Fridericia’s formula
(QTcF) in patients with advanced cancer.
Methods. Patients received intravenous ramucirumab (10
mg/kg) every 21days for 3 cycles.The first 16patients received
moxifloxacin (400mgorally), anantibiotic associatedwithmild
QT prolongation as a positive control. During cycle 3,
determination of QTcF prolongation was made with triplicate
electrocardiograms at multiple time points to compare with
baseline.
Results. Sixty-six patients received therapy; 51 patients
completed 9 or more weeks of therapy for the complete
QTcF evaluation period. The upper limit of the 90% two-
sided confidence intervals for the least square means of
change in QTcF from baseline at each time point was less
than 10 milliseconds. Concentration-QTcF analysis showed
a visible, but not significant, negative association between
ramucirumab concentration and QTcF change from
baseline.
Conclusion. Ramucirumab at a dose of 10mg/kg administered
every 21 days for 3 cycles did not produce a statistically or
clinically significant prolongation of QTcF. The Oncologist
2016;21:402–403f
DISCUSSION
QTcF correction change from baseline was the primary
endpoint for this study. Fifty-one patients received at least
9 weeks of ramucirumab (10 mg/kg) plus diphenhydramine
treatment (the complete corrected QT [QTc] evaluation
period). Using the time-matched QTcF values from day21 as
the baseline, repeated-measures analysis of covariance
showed that the upper limit of the two-sided 90% confidence
intervals of the least squaremeans of change frombaseline for
QTcF values was less than 10 milliseconds at all study time
points in cycle 3 (Fig. 1). The first 16 patients received
treatment with moxifloxacin (400 mg orally), an antibiotic
associated with mild QTc prolongation, which demonstrated
assay sensitivity.
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The relationship between ramucirumab concentrations
and change in QTcF was assessed using data from time points
at which both the electrocardiogram data and the concen-
tration data were available; the time-matched mean change
from baseline QTcF was analyzed for correlation with the
serum concentration of ramucirumab, using linear mixed
models (Fig. 2).The slope of themodel in this analysiswas not
statistically significantly different from zero. The estimated
value of the slope was 20.00207, showing a small negative
association between concentration of ramucirumab and
the change from baseline in QTcF. Mean ramucirumab
concentration-time profiles at cycles 1 and 3 were very
similar, with slightly higher mean concentrations for cycle 3,
reflecting a small amount of accumulation following 3 doses
of ramucirumab.
Safety analyses included all treated patients (n5 66).
Most treatment-emergent adverse events (TEAEs) in
patients receiving ramucirumab were consistent with
the known adverse event (AE) profile. Sixty-five patients
experienced at least one TEAE, regardless of causality.
Forty-two patients (63.6%) experienced at least one TEAE
considered related to ramucirumab; the most common
were headache (16.7%; 1.5% grade 3), nausea (15.2%),
hypertension (10.6%; 4.5% grade 3), and vomiting
(10.6%).
This phase II study demonstrated that ramucirumab
did not produce a prolongation of QTcF. The 90% two-
sided (95% one-sided) upper confidence limit did not
exceed 10 milliseconds. This conclusion is also supported
by concentration-QTcF modeling, which showed a visible
but not significant negative association between concen-
tration of ramucirumab and change from baseline in QTcF.
TRIAL INFORMATION
Disease Advanced Cancer/Solid Tumor Only
Stage of disease / treatment Metastatic / Advanced
Prior Therapy No designated number of regimens
Type of study - 1 Phase II
Type of study - 2 Single Arm
Primary Endpoint To determine the effect of ramucirumabon theQT/QTc interval in
patients with advanced cancer.
Secondary Endpoint Safety
Additional Details of Endpoints or Study Design Patients who experienced ongoing clinical benefit may have
continued to receive study therapy until there was
documented progression of disease, intolerable toxicity, or
withdrawal of consent. A follow-up evaluationwas conducted
including adverse event assessment. Routine monitoring,
including radiographic evaluation of disease, was continued
as necessary to confirm patient eligibility to continue in the
trial.
Investigator’s Analysis Active and should be pursued further.
Figure 1. Graph showing 90% confidence interval of change from
baseline at cycle 3 for QTcF after ramucirumab plus diphenhy-
dramine treatment. Red dotted line and blue dotted line indicate
10- and 5-millisecond time points, respectively. The scale of the
x-axis (time) is non-uniform.
Abbreviation: QTcF, QT corrected by Fridericia’s formula.
Figure 2. QTcF changes from baseline versus total drug concen-
trations at cycle 3 for the evaluable population. Mean Cmax5 571
mg/mL.Meanchange inQTcFatmeanCmax52.8milliseconds (90%
CI:23.8 to 9.5).
Abbreviations: CI, confidence interval; QTcF, QT corrected by
Fridericia’s formula.
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DRUG INFORMATION
Drug 1
Generic/Working name Ramucirumab
Trade name Cyramza
Company name Eli Lilly and Company
Drug type Antibody
Drug class Angiogenesis - VEGF
Dose 10 mg/kg
Route IV
Schedule of Administration Every 21 days
PATIENT CHARACTERISTICS
Number of patients, male 37
Number of patients, female 31
Age Median (range): 63.5 years (19–86 years)
Performance Status: ECOG 0— 17
1— 46
2— 3
Unknown— 2
PRIMARY ASSESSMENT METHOD
Control Arm: Total Patient Population
Number of patients screened 76
Number of patients enrolled 68
Number of patients evaluable for toxicity 66
Number of patients evaluated for efficacy 0
ADVERSE EVENTS
Adverse Events at All Dose Levels, All Cycles
Name *NC/NA 1 2 3 4 5 All Grades
Fatigue 68% 15% 14% 3% 0% 0% 32%
Nausea 67% 17% 14% 2% 0% 0% 33%
Dyspnea 69% 12% 14% 5% 0% 0% 31%
Abdominal pain 72% 9% 11% 8% 0% 0% 28%
Headache 72% 18% 5% 5% 0% 0% 28%
Diarrhea 76% 21% 3% 0% 0% 0% 24%
Vomiting 77% 9% 11% 3% 0% 0% 23%
Dehydration 81% 2% 11% 6% 0% 0% 19%
Constipation 84% 8% 6% 2% 0% 0% 16%
Dizziness 84% 14% 2% 0% 0% 0% 16%
Hypertension 85% 0% 9% 6% 0% 0% 15%
Fever 85% 12% 3% 0% 0% 0% 15%
Anorexia 67% 17% 14% 2% 0% 0% 33%
Edema limbs 81% 12% 5% 2% 0% 0% 19%
Cough 79% 18% 3% 0% 0% 0% 21%
Adverse Events Legend
Treatment-emergent adverse events reported for$10 patients regardless of causality (safety population, n5 66)
*No Change from Baseline/No Adverse Event
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SERIOUS ADVERSE EVENTS
Name Grade Attribution
Gastrointestinal hemorrhage 2 Possible
Infusion-related reaction 2 Probable
Hepatic failure 4 Possible
Dehydration 3 Unrelated
Pulmonary embolism 3 Unrelated
Deep vein thrombosis 3 Possible
Hypertension 2 Definite
Serious Adverse Events Legend
Serious adverse events considered related to study drug (safety population, n5 66)
PHARMACOKINETICS/PHARMACODYNAMICS, CYCLE 1
n 61
Cmax 485 mg/mL
AUC 67,400 mg3 h/mL
Half-life 148 hours
Volume of distribution 2,290 mL
Clearance 11.6 mL/h
PHARMACOKINETICS/PHARMACODYNAMICS, CYCLE 3
n 47
Cmax 571 mg/mL
AUC 69,900 mg3 h/mL
Half-life 189 hours
Volume of distribution 2,560 mL
Clearance 10.7 mL/h
Note: Please refer to Table 2 for summary of major pharmacokinetic parameters.
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Pharmacokinetics / Pharmacodynamics Correlative Endpoints Met
Investigator’s Assessment Active and should be pursued further
Vascular endothelial growth factor (VEGF) and VEGF
receptor-2 (VEGFR-2) contribute to angiogenesis, which plays
a role in tumor growth and metastasis. Ramucirumab is a
recombinant human immunoglobulin G1 (IgG1) monoclonal
antibody that specifically binds to VEGFR-2, inhibiting VEGF-
mediated signaling [1]. The International Conference on
Harmonization E14 guidance specifies that all drugs should
undergo a formal clinical evaluation early in clinical develop-
ment to assess the potential for QT/QTc prolongation [2]. The
exact timing of QT/QTc prolongation following ramucirumab
administration, if existent,wasnot knownbefore initiating this
study. This was a multicenter, open-label, single active-arm,
phase II study todetermine if treatmentwith ramucirumab (10
mg/kg) caused prolongation of the QT/QTc interval in patients
with advanced cancer.
A total of 68 patients (37 men and 31 women) between the
agesof19and86yearswithadvancedcancerofsolid-tumororigin
enrolled in this study (Table 1). Patients with an implantable
pacemaker or automatic implantable cardioverter defibrillator
were not eligible for this study. Patients with a congenital long
QT syndrome; a prolonged QTc interval on pretreatment
electrocardiogram (ECG) of longer than 450 milliseconds, using
both Bazett’s (QTcB) and Fridericia’s (QTcF) QT correction; a
clinically relevant abnormality on the ECG that prevented an
accurate measurement of the QT interval; or using a medication
that was known to prolong the ECG QT interval were excluded.
Patients with a history of risk factors for ventricular tachycardia or
torsadesdepointes, fainting,unexplained lossofconsciousness,or
convulsions were also excluded from participation. Patients
received 10 mg/kg of ramucirumab every 21 days. Sixty-six
patients received at least one dose of study drug and comprised
the safety population. Fifty-one patients received at least 9weeks
of therapy (the complete QTc evaluation period). Patients who
experienced ongoing clinical benefit may have continued to
receive study therapy until therewas documented progression of
disease, intolerable toxicity, orwithdrawal of consent. A follow-up
evaluation was conducted, including adverse event assessment.
Routine monitoring, including radiographic evaluation of disease,
was continued as necessary to confirm patient eligibility to
continue in the trial.
Serial blood samples were taken from patients following
the initial infusion (cycle 1) and the third infusion (cycle 3).
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Ramucirumab serum concentrations were measured by a
bridging enzyme-linked immunosorbent assay, as previously
described [3]. Profiles were very similar, with slightly higher
meanconcentrations forcycle3, reflecting thesmall amountof
accumulation following 3doses of ramucirumab (Fig. 3).Major
pharmacokineticparameters following intravenous infusionof
10 mg/kg ramucirumab in cycles 1 and 3 are summarized in
Table 2.
The QTcF change from baseline was the primary endpoint
for this study. QT/QTc prolongation was determined with
triplicateECGsatmultiple timepointsafter the initialdose, and
at steady state at a therapeutic dose level.The first 16 patients
enrolled in the study received 1 dose of moxifloxacin (400 mg
orally), an antibiotic associated with mild QTc prolongation, 1
week before receiving ramucirumab treatment, to demon-
strate assay sensitivity. The mean moxifloxacin-induced QTcF
prolongation exceeded 10 milliseconds and the lower 90%
confidence intervals (CIs) exceeded 5 milliseconds at 8
postdose time points (Fig. 4).
Pretreatment with diphenhydramine (25–50 mg) was
required before the administration of ramucirumab for cycles
1–4.The90%CIofchange fromtime-matchedbaseline(day21)
for QTcF at cycle 3 is shown in Figure 1. The diphenhydramine
infusion occurred between 00:00 and 00:15, and the ramucir-
umab infusion occurred between 00:15 and 1:15. Using the
time-matched QTcF values from day 21 as the baseline,
repeated-measures analysis of covariance showed that the
upper limit of the two-sided 90%CI of the least squaremeans
of change from baseline for QTcF values was less than
10milliseconds at all study time points in cycle 3. Categorical
outlier analysis for cycle 3 showed 2 patients (3 time points)
with a QTcF value of longer than 450 milliseconds and no
longer than 480 milliseconds. No patient had a QTc value of
longer than 480 milliseconds or QT, QTcB, or QTcF values of
500 milliseconds or longer in this population.
Time-matched concentration change frombaseline in QTcF
analysis demonstrated the slope of the model in this analysis
was not statistically significantly different from zero. The
estimated value of the slope was 20.00207, showing a small
negative association between ramucirumab concentration and
thechange frombaseline inQTcF (Fig. 2).Theestimatedvalueof
mean change inQTcFwas 2.8milliseconds (90%CI:23.8 to9.5)
at a geometric mean maximum serum concentration (Cmax) of
571mg/mL (range: 272–1820 mg/mL) during cycle 3.
Sixty-five patients experienced at least one treatment-
emergent adverse event (TEAE), regardless of causality. The
TEAEs,regardlessofcausality, reportedforat least10%ofpatients
are presented in Table 3. Forty-two patients (63.6%) had at least
1 TEAE that was considered related to ramucirumab. The most
common grade 3 TEAE considered related to ramucirumab was
hypertension (n5 3; 4.5%). Eleven patients (16.7%) experienced
at least 1 serious adverse event (SAE) considered related to
ramucirumab; 8 (12.1%) were grade $3 (Table 4). Thirty-two
patients(48.5%)experiencedat least1SAEregardlessofcausality.
Sixteenpatientsdiedduringthestudy.Elevenpatientsdiedwithin
30 days of the last dose of ramucirumab; 5 patients died more
than 30 days after the last dose of ramucirumab. Disease
progression was indicated as the primary cause of all of these
deaths.
Ramucirumab is approved by the U.S. Food and Drug
Administration for metastatic gastric cancer (REGARD and
RAINBOWtrials), non-small cell lung cancer (REVEL trial), and
metastatic colorectal cancer (RAISE trial) [4–7]. Some VEGF
inhibitors can prolong the QTc interval. Vandetanib, which
inhibits VEGFR and epidermal growth factor receptor
signaling, significantly prolonged QTc interval [8]. An
evaluation of sunitinib, a multitargeted tyrosine kinase
inhibitor, demonstrated a dose-dependent effect on QT
interval [9]. Based on the overall assessment, this study
demonstrated that ramucirumab at a dose of 10 mg/kg
administered every 21 days for 3 cycles did not produce a
prolongation of QTcF. This was also supported by time-
matched concentration change from baseline in QTcF anal-
ysis, which showed a visible but not significant negative
association between ramucirumab concentration and
change from baseline in QTcF.
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FIGURES AND TABLES
Figure 3. Mean ramucirumab concentration-time profiles following the first (cycle 1) or third (cycle 3) dose of 10 mg/kg ramucirumab.
Figure4. Graphshowing90%confidence intervalofchange frombaseline forQTcFaftermoxifloxacin treatment.Reddotted lineandblue
dotted line indicate 10- and 5-millisecond time points, respectively. The scale of the x-axis (time) is non-uniform following the 4-hour
measurement.
Abbreviation: QTcF, QT corrected by Fridericia’s formula.
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Table 1. Baseline patient characteristics (enrolledpopulation,
n5 68)
Characteristic n (%)
Sex
Male 37 (54.4)
Female 31 (45.6)
Age, years
Median (range) 63.5 (19–86)
18 to,65 41 (60.3)
$65 27 (39.7)
Race
White 62 (91.2)
Black 5 (7.4)
Asian 1 (1.5)
Ethnicity
Hispanic or Latino 4 (5.9)
Non-Hispanic or Latino 64 (94.1)
ECOG PS
0 17 (25.0)
1 46 (67.6)
$2 3 (4.4)
Missing 2 (2.9)
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group
Performance Status.
Table 2. Summary of ramucirumab pharmacokinetic parameters following administration of 10 mg/kg ramucirumab
Geometric mean (geometric CV%), 10 mg/kg every 3 weeks
PK parameter Cycle 1: first dose (NPK5 61)
a Cycle 3: third dose (NPK5 47)
b
Cmax or Cmax,ss (mg/mL) 485 (43) 571
b (41)
t1/2 (hours) 148
a (36) 189b (33)
AUC(0-‘) or AUCt,ss (mg3 h/mL) 67,400
a (38) 69,900b (41)
CL or CLss (mL/h) 11.6
a (35) 10.7b (41)
Vss (mL) 2,290
a (36) 2,560b (46)
RA,Cmax 1.12
b (57)
RA,AUC 1.11
b (38)
anPK5 59 for t1/2; nPK5 58 for AUC(0-‘), CL, and Vss.
bnPK5 45 for Cmax,ss, and RA,Cmax; nPK5 38 for AUCt,ss, CLss, and RA,AUC; nPK5 37 for t1/2; nPK5 34 for Vss.
Abbreviations: AUC, area under the concentration-timecurve; AUC(0-‘), AUC from time0extrapolated to infinity; AUCt,ss, AUCover thedosing interval at
steady state; CL, total body clearanceofdrug calculated after intravenous administration; CLss, clearance at steady state; Cmax,maximumobserved serum
concentration; CV%, percent coefficient of variation; NPK, number of subjects used in pharmacokinetic analysis; nPK, number of pharmacokinetic
observations; PK, pharmacokinetic; RA,AUC, accumulation ratio based on AUC; RA,Cmax, accumulation ratio based on Cmax; t1/2, apparent terminal
elimination half-life; Vss, volume of distribution at steady state.
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Click here to access other published clinical trials.
Table 3. Treatment-emergent adverse events reported for at least 10% of patients regardless of causality (safety population,
n5 66)
Preferred term Any grade,a n (%) Grade ‡3,a n (%)
Decreased appetite 21 (31.8) 1 (1.5)
Fatigue 21 (31.8) 2 (3.0)
Nausea 21 (31.8) 1 (1.5)
Dyspnea 20 (30.3) 3 (4.5)
Abdominal pain 18 (27.3) 5 (7.6)
Headache 18 (27.3) 3 (4.5)
Diarrhea 16 (24.2) 0 (0.0)
Vomiting 15 (22.7) 2 (3.0)
Cough 14 (21.2) 0 (0.0)
Dehydration 12 (18.2) 4 (6.1)
Edema peripheral 12 (18.2) 1 (1.5)
Constipation 10 (15.2) 1 (1.5)
Dizziness 10 (15.2) 0 (0.0)
Hypertension 10 (15.2) 4 (6.1)
Pyrexia 10 (15.2) 0 (0.0)
Chills 9 (13.6) 0 (0.0)
Abnormal weight loss 8 (12.1) 1 (1.5)
Arthralgia 7 (10.6) 0 (0.0)
Asthenia 7 (10.6) 0 (0.0)
Depression 7 (10.6) 0 (0.0)
aNational Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 was used for adverse event grading [10].
Table 4. Serious adverse events considered related to study drug (safety population, n5 66)
Serious adverse event Any grade, n (%) Grade ‡3, n (%)
Patients with any adverse event 11 (16.7) 8 (12.1)
Gastrointestinal hemorrhage 1 (1.5) 0 (0.0)
Infusion-related reaction 1 (1.5) 0 (0.0)
Hepatic failure 1 (1.5) 1 (1.5)
Dehydration 1 (1.5) 1 (1.5)
Pulmonary embolism 1 (1.5) 1 (1.5)
Deep vein thrombosis 2 (3.0) 2 (3.0)
Hypertension 1 (1.5) 0 (0.0)
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